Open AccessPharmacokinetic Considerations to Maximize an ADC’s Therapeutic Index
Author(s) -
Greg M. Thurber
Publication year - 2019
Publication title -
adc review
Language(s) - English
Resource type - Journals
ISSN - 2327-0152
DOI - 10.14229/jadc.2019.11.12.001
Subject(s) - monoclonal antibody , antibody drug conjugate , therapeutic index , pharmacokinetics , conjugate , drug delivery , drug , medicine , cancer research , antibody , pharmacology , computer science , nanotechnology , immunology , materials science , mathematics , mathematical analysis
The Antibody-drug Conjugate (ADC) field is poised for several significant advances in solid tumors as the industry has built upon knowledge gained over the past several years.The biggest challenge facing clinical translation of these drugs is improving the therapeutic index (TI). With the use of proven targeting agents (monoclonal antibodies) and proven cancer cytotoxins (e.g. microtubule inhibitors and DNA alkylating agents), increasing delivery to cancer cells while avoiding healthy tissue is the key issue in improving the TI.